Histogen is a regenerative medicine company focused on developing patented, innovative technologies for aesthetic and therapeutic markets that replace and regenerate tissues in the body. The Company currently has three product candidates in clinical development intended to address what Histogen believes to be underserved, multi-billion dollar global markets: a treatment for hair loss, a dermal filler and a treatment for joint cartilage repair.
Histogen, Inc., a Delaware Corporation, was founded in 2007. The Company is focused on developing innovative products based upon Histogen’s unique technology that utilizes the proteins and growth factors produced by cells grown under simulated embryonic conditions. The Company is headquartered in San Diego, California.
Histogen founder Dr. Gail Naughton is a highly respected scientist with extensive experience in the field of tissue engineering and regenerative medicine. Dr. Naughton discovered the potential of proteins and growth factors produced by hypoxia-induced multipotent cells for therapeutic and biomedical applications, and developed Histogen’s unique technology process to create products based on these proteins. The technology is protected by patent families filed in the US and across key geographies.